Aerska, which uses brain shuttle technology to deliver RNAi therapeutics to the brain, announced the close of a $39 million Series A financing round, bringing its total funding to $60 million. EQT ...

Amyloid is increasingly ceding ground in Alzheimer’s disease R&D to new approaches targeting inflammation, immune processes, ...

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Hello, everyone. I'm Pete Stavropoulos biotech analyst at Cantor and welcome to our first of 2 webinars with Voyager to discuss its blood-brain barrier crossing technologies. It's an exciting time for ...

(A) Experimental schematic diagram. (B to D) PBM therapy apparatus (C) including a touchscreen control (B) and a lens (D). (E) The rats were fixed in a stereotaxic apparatus during PBM therapy. (F) ...